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ABSTRACT 
Background Actinic keratoses (AKs) are commonly diagnosed clinically. Actinic 
keratosis area and severity index (AKASI) is a new easy-to-use tool to assess the 
severity of AK on the head.  
Objective. To determine the association between chronically UV-induced tumours 
such as basal cell carcinomas (BCC) or squamous cell carcinomas (SCC) and 
AKASI.  
Methods We performed a retrospective analysis of patients who had undergone 
oncological surgery due to UV-induced tumours and who were assessed for AKASI 
and Physician’s Global Assessment (PGA) prior to surgery. Statistical analysis was 
performed to evaluate correlation between AKASI, PGA and invasive carcinomas.  
Results Of the 210 patients included, 26 patients had histologically diagnosed SCCs 
and presented with a median (range) AKASI of 6.9 (0 – 13.0) and PGA of 2 (0 - 4). In 
contrast, the 82 patients with BCCs showed a median (range) AKASI of 3.3 (0 -15.2) 
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and PGA of 1 (0 - 4). The Mann-Whitney U test showed significant differences (p= 
0.0018) between AKASI of patients with SCC and BCC. In addition, we found a 
significantly higher AKASI in patients with SCC compared to patients with non-
invasive lesions like AK and Bowen disease (BD) (p= 0.0275). Spearman's 
coefficient of rank correlation between AKASI and PGA indicates that these 
measures of AK severity were strongly correlated (p< 0.0001; r = 0.90; 95%CI 0,865 
to 0,920). 
Conclusions Patients with SCC show significantly higher AKASI than patients with 
BCC or patients without invasive tumours. Hence, AKASI may be used to stratify risk 
for developing invasive SCC. 
 
INTRODUCTION 
Actinic keratoses (AK) are commonly seen in dermatological practice1, 2 They are 
regarded as early in situ carcinomas and bear the potential to progress into an 
invasive squamous cell carcinoma (SCC), which may subsequently metastasize. 
AKs are mainly induced by chronic exposure to UV-radiation and located on sun-
exposed sites such as the scalp/face, décolletage, forearms, back of the hands and 
lower legs.3-6 As the entire area of sun-exposed skin is affected by both clinical and 
subclinical disease resulting in field cancerisation, treatment approaches ideally 
need to address all AK lesions and the entire affected field.7  
Due to a change in leisure activities in the past few decades and a demographic 
change in industrial countries, increasing incidence of non-melanoma skin cancer 
(NMSC) and AKs in particular, have been observed.2 AKs are regarded as chronic 
disease and as the prevalence continues to rise, this has led to an increasing 
number of episodes of treatment and the options available, resulting in increasing 
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costs to the health service. Commonly, AKs are diagnosed clinically and their 
severity is graded according to a classification scheme introduced by Olsen et al.8 
The main limitation of this scoring system is that it only grades discrete AK lesions 
according to their overall thickness and does not take into account the entire area 
affected by AK. To overcome this problem a new assessment tool was recently 
introduced. The “actinic keratosis area and severity index” (AKASI) quantitatively 
evaluates the severity of AKs across the entire affected area of the head.9  
Thus, AKASI is a new grading tool which provides the possibility to objectively 
monitor and compare disease progression. It is analogous to established scoring 
systems of other chronic diseases i.e. the psoriasis area and severity index (PASI). 
To assess AKASI, the head is divided into four areas and each area is evaluated to 
its approximate relative size and the severity of three characteristic clinical signs of 
AK (distribution, erythema, thickness).  
Currently clinical and histological classification schemes lack the predictive power to 
determine carcinoma risk of single AKs.2, 7 It would therefore be valuable to have a 
scoring system which assesses the overall risk of an individual patient developing 
invasive carcinoma, but thus far, no clinical classification scheme has been reported 
which stratifies the severity of AKs and the risk of developing invasive carcinomas 
such as SCC or BCC.  
The aim of this study was to analyse patients who have undergone oncological 
surgery due to UV-induced tumours on the head. All patients were assessed using 
the PGA and AKASI prior to surgery. This is the first study to show a correlation 
between AKASI and PGA in clinical dermatological practice. 
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MATERIALS AND METHODS 
Study population 
This retrospective study was conducted according to the Declaration of Helsinki and 
performed at the Skin Cancer Centre of the Ruhr-University Bochum (Bochum, 
Germany). The study was approved by the ethics review board of the Ruhr-
University Bochum. We searched our database consecutively from January 2017 to 
May 2017 for all patients who had undergone oncological surgery (surgical and 
shave excisions) due to UV-induced tumours (AK, BD, SCC and BCC) located on 
the head and had an existing AKASI and PGA. Patients under immunosuppressive 
therapy were excluded from this study.  
 
Data assessment 
Prior to surgery for UV-induced tumours on the head, AKASI and PGA were 
evaluated in all patients. These assessments were performed by one investigator 
(LS). AKASI is part of our AK management and determined routinely. For area 
assessment of the AKASI, the head was divided into four areas: scalp, forehead, left 
cheek, ear, nose, and chin as well as right cheek, ear, nose and chin. Each area on 
the head affected by AKs was given a weighting with 40% to the scalp and 20% 
each to the other three areas. The severity of each area was evaluated by three 
characteristic clinical signs of AKs (distribution, erythema, thickness) using a 
quantitative scale from 0 (none) to 4 (severe). Finally, all sub scores for each area of 
the head were added to give a total AKASI of the head, which ranged from 0 to 18. 
For PGA scoring, the following categories were used: ‘None’ (0), ‘Light’ (1), 
‘Moderate’ (2), ‘Severe’ (3) and ‘Very severe’ (4).  
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Statistical analysis 
Data analysis was performed using the statistical package MedCalc software version 
17.4.4 (Ostend, Belgium). Distribution of data was assessed by the D`Agostino-
Pearson test. In the case of normal distribution, data were expressed as mean and 
standard deviation (SD), otherwise as median and range. Data were analyzed using 
the Spearman's coefficient of rank correlation and Mann-Whitney U test for 
independent sample analysis. P-values less than 0.05 were considered statistically 
significant. 
 
.RESULTS 
210 patients with a median (range) age of 77 (42-95) years were included in this 
study. Two thirds of patients were male (66.2%) and most patients had Fitzpatrick 
skin type II (61.9%). More than half of the study group had a positive history of 
invasive skin cancer (52.4%) and increased UV-exposure (57.1%). Further 
demographic and clinical characteristics are shown in table 1.  
Overall, 636 lesions on the head were surgically treated. Histological evaluation 
revealed AKs in 298 (46.9%), BD in 88 (13.8%), SCC in 32 (5.0%), BCC in 118 
(18.6%) and other tumours such as seborrhoeic keratosis in 104 (16.4%) cases 
(Table 1). Further characteristics of the 32 SCCs are shown in table 2. Highly 
significant differences between AKASI in male and female patients were observed (p 
< 0.0001) (Fig 1). 
Patients (n = 26) with SCC showed median (range) AKASI of 6.9 (0 – 13.2) and PGA 
of 2.0 (0 - 4). In contrast, patients exclusively presenting AKs (n = 106) showed a 
median (range) AKASI of 4.6 (0-15.5) and PGA of 2.0 (0-4.0), whereas patients (n = 
82) with BCC had an AKASI of 3.3 (0 – 15.2) and a PGA of 1.0 (0 – 4.0). The Mann-
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Whitney U test showed significant differences (p = 0.0018) between AKASI of 
patients with SCC and BCC (Fig. 2). The Spearman's coefficient of correlation shows 
a strong association between the  AKASI and the number of lesions on the head 
having been indicated to receive surgery due to suspicion of invasiveness (P < 
0.0001; r = 0.55; 95% CI 0.44 to 0.63) (Table 1). 
Subgroup analysis of patients with BCC or SCC and AKASI > 0 showed that patients 
with SCC (n = 24) had a higher median (range) AKASI of 7.1 (1.4 – 13.2) and PGA 
of 2.5 (1.0 – 4.0) compared to patients with BCC (n = 59) who had an AKASI of 4.8 
(1.0 – 15.2) and PGA of 2.0 (1.0 – 4.0). The Mann-Whitney U test showed significant 
differences (p = 0.0304) between AKASI in patients with SCC and BCC (Fig. 3). 
Patients with solely non-invasive tumours (n = 43) such as AKs and BD had a 
median (range) AKASI of 5.0 (0.6 – 11.2). A significant difference (p = 0.0275) 
between AKASI of patients with AKs/ BD and SCC was observed (Fig. 3).  
The Spearman's coefficient of rank correlation between AKASI and PGA indicated 
that these measures of AK severity were strongly correlated (P < 0.0001; r = 0.90; 
95% CI 0.87 to 0.92). Moreover, AKASI clearly discriminated between different PGA 
categories (Fig. 4). In 36 patients without any AKs a PGA rating of `none´ and a 
median (range) AKASI of 0 (0 - 3.6) were observed. The median (range) AKASI 
increased from 2.8 (0.6 - 8.0) for a PGA classification of ‘light’ to 5.8 (1.8 – 10.2) for 
a PGA classification of ‘moderate’, 8.4 (5.0 -13.2) for a PGA classification of ‘severe’, 
and 11.5 (6.8 – 15.8) for a PGA classification of ‘very severe’. 
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DISCUSSION 
AKs are located on chronically sun-exposed areas and are regarded as major 
predictors for actinically damaged skin.10 The “actinic keratosis area and severity 
index” has recently been reported and can be used to assess the entire sun-
damaged field on the head. It is based on the evaluation of clinical signs of AK and is 
assessed in each of 4 areas of the head. Thus, individual AK lesions, as well as field 
cancerisation, can be measured objectively and AKASI can provide inter- and 
intraindividual comparable indices of disease severity.9 To our knowledge, this is the 
first study which compares AKASI to NMSC occurring on the head in clinical 
practice.  
The majority of studies and clinical trials for AKs have been based on AK lesion 
counts or Olsen`s lesion classification.11 The main limitation of these scoring 
systems is that they assess only the severity of individual lesions and do not 
consider the entire area affected by AK.9 To our knowledge, our study is the first to 
demonstrate AKASI cut off thresholds with respect to the incidence of invasive 
NMSC. As most SCC lesions (between 82% and 97%) arise from AK or in proximity 
of AK, AKASI can become a powerful tool for risk stratification in individual 
patients.12, 13 Our data indicate that patients with an AKASI between 6.9 and 7.1 or 
higher may have an increased risk of an invasive SCC. Therefore, we propose that 
AKASI of over 7 may suggest an increased risk of SCC transformation and thus 
greater vigilance may be required in these patients. Conversely patients with in situ 
lesions (AK and BD) had significantly lower AKASI than patients with SCC. A 
“typical” AK patient is described to have 6 to 8 AK lesions and the annual risk of 
developing SCC ranges from 0.15% to 80%, accordingly.5, 13-16 In patients with 
multiple AK lesions (more than 15), the risk of SCC is 10 to 15 times higher than in 
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people with no AKs.17 As AKs are one of the strongest predictors of SCC 
development, further larger studies using AKASI are required to ascertain more 
robust thresholds and the risk of developing SCC.18  
AKs are indicative of photodamage and thus associated with an increased risk of 
BCC,19 which is lower than the risk of developing a SCC.20 Our study shows that 
only 59.3% of the patients with BCC presented with AKs (AKASI > 0) compared to 
93.8% of patients affected by SCC. Moreover, the comparison of AKASI showed 
significant differences between patients with BCC and SCC in the full cohort and 
when patients with AKASI of zero were excluded. Our study shows that AKASI is 
significantly higher in patients with SCC than those with AK/BD and BCC, and could 
therefore be used in future risk stratification systems. Furthermore, our data confirm 
for the first time the well-known association between AKs and SCC as demonstrated 
by AKASI. Until now, existing data have been evaluated by aforementioned lesion 
based counts and classifications.8   
Our study has confirmed that AKASI was clearly able to discriminate between 
different PGA categories in a much larger cohort than in the pivotal study.9 The PGA 
categories none, mild, moderate and severe showed similar correlation with AKASI 
as the pivotal study. The PGA category “very severe”, however, exhibited a higher 
AKASI than the pivotal study. This might be related to a larger study population and 
inclusion of more severely affected patients who were admitted for surgery. After 
reviewing the pivotal study and our current study data, we would propose that scores 
around 3, 5.5, 8.5 and > 11 correspond to mild, moderate, severe and very severe 
disease, respectively.9 In comparison to psoriasis, a PASI higher than 10 is regarded 
as moderate to severe disease.21 Hence, we would suggest an AKASI higher than 
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8.5 to indicate severely affected AK patients. In the future, AKASI scores may have 
an application in determining treatment options and regimens. 
On the one hand, limitations of this study include that the scores (AKASI and PGA) 
have been evaluated by only one investigator. This might have led to an 
overestimation of the correlation between AKASI and PGA. On the other hand, there 
was no risk of inter-rater variability. Another limitation of this study might be that 
patients with more lesions being suspicious for invasiveness received more surgical 
interventions than patients with less noticeable lesions. A strong correlation between 
the number of lesions with intervention per patient and AKASI has been shown in 
this study. Hence, there might have been a higher risk to detect invasive tumours in 
patients with higher AKASIs due to more frequently performed excisions. 
Nevertheless, people with more severe sun-damaged skin and thus high AKASIs 
may just have more invasive NMSC such as SCC as a matter of fact.  
In conclusion, our study shows that AKASI is a reliable objective tool which can be 
used to assess field damage in clinical practice. The scores are associated with 
known epidemiological data with higher scores in men and those with SCC. Our 
study delineates thresholds for disease severity and the risk of developing invasive 
carcinomas, especially SCC. Further longitudinal studies are required to investigate 
the correlation between AKASI and SCC risk. This may in the future lead to risk 
stratified therapy. 
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TABLE LEGEND 
Table1. Demographic and clinical characteristics (N=210) 
Characteristic n (%) 
Sex 
 Male 
 Female 
 
139 (66.19) 
71 (33.81) 
Age, years 77 (42-95)a 
Skin Type (Fitzpatrick) 
 I 
 II 
 III 
 IV+V 
 
77 (36.7) 
130 (61.9) 
3 (1.4) 
0 (0) 
UV Exposure (increased) 
 leisure activities 
 occupational 
 artificial 
120 (57.1) 
92 (76.7)b 
37 (30.8)b 
4 (3.3)b 
AK History 
 no AK 
 first diagnosed at admission for surgery  
 previously diagnosed AK  
  mean time since first diagnosed 
 
33 (15.7) 
79 (37.6) 
98 (46.7) 
6.3 (years) 
Skin cancer history (invasive) 
 BCC 
 SCC 
110 (52.4) 
87 (79.1)b 
30 (27.3) b 
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 KA 
 Other (e.g. malignant Melanoma) 
3 (2.7)b 
31 (28.2)b 
Surgical sites on head (mean sites per patient) 
 patients with > 1 surgical site 
636 (3.03) 
119 (56.7) 
Of these 636 lesions, histologically diagnosed as 
 AK 
 BD 
 SCC 
 BCC 
 Other (e.g. seborrhoeic keratosis, scar)  
 
298 (46.9) 
88 (13.8) 
32 (5.0) 
118 (18.6) 
104 (16.4) 
Correlation between lesions with intervention and AKASI 
 patients (n = 90) with 1 lesion  
 patients (n = 41) with 2 lesions  
 patients (n = 79) with 3 or more lesions 
 
1.9 (0-11.4)a 
5.2 (0-13.2)a 
7.7 (0-15.8)a 
AK, actinic keratosis; AKASI, actinic keratosis area and severity index; BCC, basal 
cell carcinoma; BD, Bowen disease; KA, keratoacanthoma; SCC, squamous cell 
carcinoma 
aData are median (range); b% referring to absolute value of the headline in this row  
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Table 2. Clinical characteristics of SCC (N=32) and patients´ characteristics (N=26) 
Characteristic  n (%) 
SCC lesions total 
 patients with SCC 
 patients with 1 SCC 
 patients with >1 SCC 
32 (5.0)* 
26 (12.4)# 
22 (10.5) # 
4 (1.9) # 
Tumour thickness  
 Tumour thickness < 4 mm 
  mean tumour thickness < 4 mm 
 Tumour thickness ≥ 4 mm 
  mean tumour thickness ≥ 4 mm 
2.55 (0.4–14.4)a 
20 (62.5) 
1.45 (0.4-3.1)a 
12 (37.5) 
5.5 (4.12-14.4)a 
Invasion depth´s (Clark´s level) 
 into the papillary dermis (I+II) 
 to the junction of papillary and reticular dermis (III) 
 into the reticular dermis (IV) 
 into the subcutaneous fat (V) 
 
0 (0) 
2 (6.3) 
24 (75.0) 
6 (18.8) 
Histological differentiation (grading) 
 well differentiated (1)  
 moderately differentiated (2) 
 poorly differentiated (3) 
 undifferentiated (4) 
 
28 (87.5) 
3 (9.4) 
1 (3.1) 
0 (0) 
Perineural invasion 1 (3.1) 
Tumour sites 
 parietal 
 ear 
 scalp 
 cheek 
 forehead 
 nose 
 lip 
 
9 (28.1) 
6 (18.8) 
5 (15.6) 
5 (15.6) 
5 (15.6) 
1 (3.1) 
1 (3.1) 
*referring to overall lesions (636); #referring to overall patients (210); a Data are 
median (range) in mm 
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